WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary.
“I am thrilled to announce Eric’s appointment as our General Counsel and Corporate Secretary,” said Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals. “He has deep experience across all legal and compliance functions in the biotech industry and we look forward to his strategic leadership on our Executive Committee as Kala continues to evolve into a commercial organization.”
Mr. Trachtenberg has been practicing law for close to 20 years, most of which has been spent in the life sciences industry. Prior to joining Kala Pharmaceuticals, Mr. Trachtenberg served as General Counsel, Chief Compliance Officer and Corporate Secretary of Aralez Pharmaceuticals Inc. since February 2016. Previously, Mr. Trachtenberg served in similar capacities for Pozen Inc., Aralez’s predecessor, which he joined in June 2015. Mr. Trachtenberg formerly served as Deputy General Counsel at Auxilium Pharmaceuticals, Inc., from 2012 through its acquisition by Endo Pharmaceuticals in February of 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals Inc.) and remained in that position following the acquisition of Sepracor by Dainippon Sumitomo Pharma. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals, Inc. before its acquisition by Abbott. Mr. Trachtenberg began his career at Blank Rome LLP. He holds a Juris Doctorate and Master of Business Administration from Temple University and a Bachelor of Science in Management from Tulane University.
“I am honored to join Kala at this pivotal time in the Company’s development and look forward to working with the management team to further Kala’s mission of bringing innovative therapies to patients with eye diseases,” commented Mr. Trachtenberg.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
